<DOC>
	<DOCNO>NCT00109655</DOCNO>
	<brief_summary>The main purpose research study evaluate safety dose CG0070 .</brief_summary>
	<brief_title>Dose-Escalation Study CG0070 Bladder Cancer After BCG ( Bacillus Calmette-Guerin ) Failure</brief_title>
	<detailed_description>Cohorts three six patient assign receive intravesical ( bladder ) administration CG0070 either Weekly Every 4 Weeks total 6 dos .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>High grade nonmuscle invasive bladder cancer ( stage Ta , T1 and/or CIS carcinoma situ ) . High grade define G2 G3 disease . Failure least one prior treatment BCG , define evidence TCC cystoscopic exam biopsy cystoscopic exam urine cytology least 6 week last BCG treatment ECOG performance status 01 Adequate bone marrow , renal , liver coagulation function Pregnant nursing HIV positive Use anticoagulant coumadin heparin History bleed disorder Active systemic autoimmune disease chronic immunodeficiency Prior gene therapy Uncontrolled cystitis , bladder pain , bladder spasm , urinary incontinence , reduce bladder volume</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Superficial Transitional Cell Carcinoma</keyword>
	<keyword>Bacillus Calmette-Guerin ( BCG )</keyword>
	<keyword>Superficial Bladder Cancer</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>Carcinoma situ</keyword>
</DOC>